| Dr Rodrigo Silva Cavallazzi, MD | |
|
401 E Chestnut Street, #310, University Medical Associates, Louisville, KY 40202-5703 | |
| (502) 589-6788 | |
| (502) 584-8563 |
| Full Name | Dr Rodrigo Silva Cavallazzi |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 23 Years |
| Location | 401 E Chestnut Street, #310, Louisville, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851500961 | NPI | - | NPPES |
| 7100129840 | Medicaid | KY |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Louisville Hospital | Louisville, KY | Hospital |
| Jewish Hospital & St Mary's Healthcare | Louisville, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kentuckyone Health Medical Group Inc | 8820993702 | 227 |
| University Of Louisville Physicians Inc | 3476725599 | 1102 |
News Archive
The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by reducing inflammation, according to late-breaking results from the CANTOS trial presented today in a Hot Line - LBT Session at ESC Congress1 and published in the NEJM.
Now that stem cell researchers have devised an efficient way of creating new human embryonic stem cell lines, biomedical ethicists at the Stanford University School of Medicine say it's crucial to develop a unique set of protections for the women who donate their eggs to make the research possible.
Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).
The Muscular Dystrophy Association (MDA) and The ALS Association today announced a joint commitment to provide funding for a phase 2 clinical trial that will test efficacy of the NeuRx Diaphragm Pacing System (DPS) in people with amyotrophic lateral sclerosis (ALS).
› Verified 6 days ago
| Entity Name | Kentuckyone Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104875970 PECOS PAC ID: 8820993702 Enrollment ID: O20031204000080 |
News Archive
The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by reducing inflammation, according to late-breaking results from the CANTOS trial presented today in a Hot Line - LBT Session at ESC Congress1 and published in the NEJM.
Now that stem cell researchers have devised an efficient way of creating new human embryonic stem cell lines, biomedical ethicists at the Stanford University School of Medicine say it's crucial to develop a unique set of protections for the women who donate their eggs to make the research possible.
Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).
The Muscular Dystrophy Association (MDA) and The ALS Association today announced a joint commitment to provide funding for a phase 2 clinical trial that will test efficacy of the NeuRx Diaphragm Pacing System (DPS) in people with amyotrophic lateral sclerosis (ALS).
› Verified 6 days ago
| Entity Name | University Of Louisville Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366722316 PECOS PAC ID: 3476725599 Enrollment ID: O20111017000036 |
News Archive
The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by reducing inflammation, according to late-breaking results from the CANTOS trial presented today in a Hot Line - LBT Session at ESC Congress1 and published in the NEJM.
Now that stem cell researchers have devised an efficient way of creating new human embryonic stem cell lines, biomedical ethicists at the Stanford University School of Medicine say it's crucial to develop a unique set of protections for the women who donate their eggs to make the research possible.
Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).
The Muscular Dystrophy Association (MDA) and The ALS Association today announced a joint commitment to provide funding for a phase 2 clinical trial that will test efficacy of the NeuRx Diaphragm Pacing System (DPS) in people with amyotrophic lateral sclerosis (ALS).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rodrigo Silva Cavallazzi, MD 501 E Broadway, Ste 290, Louisville, KY 40202-2040 Ph: (502) 217-8347 | Dr Rodrigo Silva Cavallazzi, MD 401 E Chestnut Street, #310, University Medical Associates, Louisville, KY 40202-5703 Ph: (502) 589-6788 |
News Archive
The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by reducing inflammation, according to late-breaking results from the CANTOS trial presented today in a Hot Line - LBT Session at ESC Congress1 and published in the NEJM.
Now that stem cell researchers have devised an efficient way of creating new human embryonic stem cell lines, biomedical ethicists at the Stanford University School of Medicine say it's crucial to develop a unique set of protections for the women who donate their eggs to make the research possible.
Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).
The Muscular Dystrophy Association (MDA) and The ALS Association today announced a joint commitment to provide funding for a phase 2 clinical trial that will test efficacy of the NeuRx Diaphragm Pacing System (DPS) in people with amyotrophic lateral sclerosis (ALS).
› Verified 6 days ago
Cindy J Code, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 3950 Kresge Way, Suite 303, Louisville, KY 40207 Phone: 502-896-1880 Fax: 502-896-1887 | |
Dr. Uchenna Loretta Ozor, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 E Chestnut St Bldg Suite303, Louisville, KY 40202 Phone: 502-629-5552 Fax: 502-629-3132 | |
Mohamed Hegazi, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 529 S Jackson St, Louisville, KY 40202 Phone: 502-562-4270 | |
Dr. Michael Patrick Krease, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1169 Eastern Pkwy Ste G58, Louisville, KY 40217 Phone: 502-452-9567 | |
Dr. Ramsey Nasri Nassar, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6400 Dutchmans Pkwy, Ste 250, Louisville, KY 40205 Phone: 502-587-9660 Fax: 502-540-5615 | |
Jeanne M Thompson, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3 Audubon Plaza Dr, Ll2, Louisville, KY 40217 Phone: 502-636-8095 Fax: 502-636-8097 | |
Terrence P Donohue, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3101 Poplar Level Rd Ste 101, Louisville, KY 40213 Phone: 502-636-7444 Fax: 502-636-7112 |